Angiotensin-converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease

Kidney and Blood Pressure Research

Volumn 21, Issue 1, 1998, Pages 66-69

  Haas, M ^a   Yilmaz, N ^a   Schmidt, A ^a   Neyer, U ^a   Arneitz, K ^a   Stummvoll, H K ^a   Wallner, M ^a   Auinger, M ^a   Arias, I ^a   Schneider, B ^a   Mayer, G ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

ACE, gene polymorphism; ACE, inhibitors; Genetics; Kidney; Proteinuria

Indexed keywords

CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DNA POLYMORPHISM; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; GENOTYPE; GLOMERULOPATHY; HEMODYNAMICS; HUMAN; INTRON; KIDNEY BIOPSY; KIDNEY DISEASE; MALE; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CREATININE; DNA; ENALAPRIL; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; PROTEINURIA; SODIUM; TREATMENT OUTCOME;

EID: 7144223417     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000025845     Document Type: Article

References (21)

1. Rigat B, Hubert C, Ahlenc-Gelas F, Cambien, F, Corvol P: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels J Clin Invest 1990;86:1343-1346.
2. Hubert C, Houot AM, Corvol P, Soubrier F: Structure of the angiotensin I-converting enzyme: Two alternate promoters correspond to evolutionary steps of a duplicated gene. J Biol Chem 1991;266:15377-15383.
3. Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, Soubrier F: Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme gene controls plasma levels Am J Hum Genet 1992,51:197-205.
4. Hunley TE, Julian BA, Phillips JA, Summar ML, Yoshida H, Horn RG, Brown NJ, Fogo A, Ichikawa I, Kon V: Angiotensin-converting enzyme gene polymorphism: Potential silencer motif and impact on progression in IgA nephropathy. Kidney Int 1996,49:571-577
5. Swales DJ: The ACE gene: A cardiovascular risk factor J Coll Physicians Lond 1993;27: 106-108.
6. Marian AJ, Yu QT, Workman R, Greve G, Roberts R: Angiotensin-converting enzyme polymorphism m hypertrophic cardiomyopathy and sudden cardiac death. Lancet 1993,21:455-460.
7. Raynolds MV, Bristow MR, Bush EW, Abraham WT, Lowes BT, Zisman LS, Taft CS, Perryman B: Angiotensin-converting enzyme DD genotype in patients with ischaemic idiopathic dilated cardiomyopathy. Lancet 1993;342: 1073-1075
8. Zee YLR, Yi-Kun L, Griffiths LR, Morris BJ: Association of a polymorphism of the angiotensin I-converting enzyme gene is essential hypertension. Biochem Biophys Res Commun 1992;184:9-15
9. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zuchelli P: Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The angiotensin-convcrting enzyme inhibition in progressive renal insufficiency study group. N Engl J Med 1996;334:939-945.
10. Kamper AL, Strandgaard S, Leyssac PP: Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial. Am J Hypertens 1992;5:423-430.
11. Lewis EJ, Hunsicker LG, Bain RTP, Rohde RD: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. The collaborative study group. N Engl J Med 1993;329: 1456-1462.
12. Schmidt A, Kiener HP, Arias I, Illievich A, Barnas U, Graninger W, Mayer G: Angiotensin-converting enzyme polymorphism in patients with terminal renal failure. J Am Soc Nephrol 1996;7:314-317.
13. Dudley C, Keavny B, Stratton I, Turner R. Ratcliffe P. UK prospective diabetes study. XV. Relationship of renin-angiotensin system gene polymorphism with microalbuminuria in NIDDM Kidney Int 1995;48:1907-1911.
14. Schmidt S, Schöne N, Ritz E and the Diabetic Nephropathy Study Group: Association of ACE gene polymorphism and diabetic nephropathy. Kidney Int 1995;47:1176-1181.
15. Barnas U, Schmidt A, Illievich A, Kiener HP, Rabensteiner D, Kaider A, Prager R, Abrahamian H, Irsigler K, Mayer G: Evaluation of risk factors for the development of nephropathy in patients with IDDM: Insertion deletion angiotensin-converting enzyme gene polymorphism, hypertension and metabolic control. Diabetologia 1997,40:327-331.
16. Yoshida H, Mitarai T, Kawamura T, Kitajima T, Miyazaki Y, Nagasawa R, Kawaguchi Y, Kubo H, Ichikawa I, Sakai O: Role of the deletion polymorphism in the angiotensin-converting enzyme gene m the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 1995;96:2162-2169.
17. Moriyama T, Kitamura H, Ochi S, Izumi M, Yokojama K, Yamauchi A, Ueda N, Kamada T, Imai E: Association of angiotensin I-converting enzyme gene polymorphism with susceptibility to antiproteinuric effect of angiotensin I-converting enzyme inhibitors in patients with protemuria. J Am Soc Nephrol 1995;6:1674-1678.
18. Harden PH, Geddes C, Rowe PA, McIllroy JH, Roulton-Jones M, Stuart R, Rodger C, Junor BJR, Briggs JD, Connell JMC, Jardine AG: Polymorphism in angiotensin-converting enyzme gene and progression of IgA nephropathy Lancet 1995,345:1540-1542
19. Saiki RK, Gelfand DH, Stoffel S, Shard SJ, Higuchi R, Horn GT, Mullis KB: Primer directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988,239: 487-491.
20. Apperlo AJ, de Zeeuw D, de Jong PE: Short-term antiproteinuric response to antihypertensivc treatment predicts long-term GFR decline in patients with non-diabetic disease. Kidney Int 1994,45:S174-S178.
21. van Essen GG, Rensma PL, de Zeuw D, Sluiter WJ, Scheffer H, Apperloo A, Jong PE: Association between angiotensin-converting enzyme gene polymorphism and failure of renoprotective therapy. Lancet 1996;347:94-95.